# A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

> **NCT02008279** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** 100 mg CNTO 3157
- **BIOLOGICAL:** 300 mg CNTO 3157
- **BIOLOGICAL:** 600 mg CNTO 3157
- **BIOLOGICAL:** 300 mg CNTO 3157
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02008279
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008279, "A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT02008279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*